Tianjin Ringpu Bio-Technology's subsidiary has been approved to produce South African 1-type multi-valent foot-and-mouth disease vaccine.

Tianjin Ringpu Bio-Technology (300119.SZ) announced that its holding subsidiary Inner Mongolia Bioway Antai Bioscience Technology Co., Ltd. (referred to as "Bioway Antai") recently received the approval document for the veterinary drug product approval number from the Ministry of Agriculture and Rural Affairs. The two products "Foot-and-Mouth Disease O type, A type, and South Africa 1 type trivalent inactivated vaccine for cattle and sheep" and "Foot-and-Mouth Disease O type and South Africa 1 type bivalent inactivated vaccine for pigs" have been approved for production. The approval of these two products will further enrich the company's foot-and-mouth disease vaccine product pipeline, meeting the market demand for the prevention and control of the latest prevalent strains of foot-and-mouth disease in China. Bioway Antai has been focusing on the technology of cell suspension culture of foot-and-mouth disease vaccines for a long time. The approval of these products will help release Bioway Antai's production capacity advantages and enhance the company's market competitiveness in the field of major animal disease prevention and control. The company will actively cooperate with national epidemic prevention policies, accelerate preparations for product listing, and achieve commercial production and market supply of the products as soon as possible.